Don't forget Techinvest that there will likely be some flexibility with this....in terms of:
* A potential RMAT designation.
* Timing of a 2nd trial (eg. post market approval)
* Real world data post approval versus a conventional P3 tiral.
* Tasly's heart failure trial in China may negate the need for MSB (or future partner) to conduct a 2nd P3 trial.
Tech please try and be a little more balanced with future posting.
Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-22
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.005(0.38%) |
Mkt cap ! $1.478B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.32 | $1.28 | $975.1K | 752.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 85 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 17695 | 6 |
View Market Depth
| Last trade - 12.19pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |